Tharimmune, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 1200 ROUTE 22 EAST, BRIDGEWATER, NJ, 08807
Mailing Address 34 SHREWSBURY AVE, RED BANK, NJ, 07701
Phone 302-743-2995
Fiscal Year End 1231
EIN 842642541
Financial Overview
FY2024
$-9.41
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 3 Initial insider ownership report | February 11, 2026 | View on SEC |
| 3 Initial insider ownership report | February 11, 2026 | View on SEC |
| 3 Initial insider ownership report | February 11, 2026 | View on SEC |
| 3 Initial insider ownership report | February 11, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 3, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 2, 2026 | View on SEC |
| 8-K Current report of material events | February 2, 2026 | View on SEC |
| 8-K Current report of material events | January 26, 2026 | View on SEC |
Material Events
8-K Legal Issue January 15, 2026
High Impact
- Tharimmune is actively taking steps to regain Nasdaq compliance regarding board independence.
- A Special Meeting of Stockholders is scheduled for January 30, 2026, to elect two new independent directors.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.